GPT and atrial fibrillation: Severe adverse events (SAEs) occurred in two patients, including a grade 3 atrial fibrillation (2.5 mg/m2 cohort) and a grade 3 ALT/AST increased (3.2 mg/m2 cohort), which were treatment-related and required prolonged hospitalization.